2024
MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchBiochemically recurrent prostate cancerPositron emission tomographyPSMA-PETProstate cancerEmission tomographyCost-effective
2023
Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study.
Pouliot F, Gorin M, Rowe S, Saperstein L, Denes B, DiPippo V, Stambler N, Morris M, Siegel B. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. Journal Of Clinical Oncology 2023, 41: 61-61. DOI: 10.1200/jco.2023.41.6_suppl.61.Peer-Reviewed Original ResearchBaseline PSA levelsPET/CTLow PSA levelsPSA levelsTreatment recommendationsDisease managementLow baseline PSA levelsBiochemically recurrent prostate cancerPositive PET/CTBaseline PSA valuePhase 3 studySubset of patientsRecurrent prostate cancerProstate cancer patientsAvailable clinical informationConventional imaging resultsYears of ageDisease management plansManagement QuestionnaireEquivocal imagingEvaluable patientsNegative PETSystemic therapyDisease recurrenceInitial staging
2021
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot F, Gorin M, Rowe S, Saperstein L, Josephson D, Carroll P, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Siegel B. PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. Journal Of Clinical Oncology 2021, 39: 33-33. DOI: 10.1200/jco.2021.39.6_suppl.33.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPositive predictive valuePET/CTProstate cancerPrimary endpointPSA responseF-DCFPyL PET/CT scansF-fluciclovine PET/CTProspective phase 3 studyBiochemically recurrent prostate cancerCorrelative imaging findingsPhase 3 studyPhase III studyRecurrent prostate cancerPET/CT accuracyConventional imaging modalitiesDefinitive therapyIII studyLocal therapyMetastatic lesionsBaseline imagingImaging findingsAnatomic lesionsLower PSAF-DCFPyL
2020
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal Of Clinical Oncology 2020, 38: 5501-5501. DOI: 10.1200/jco.2020.38.15_suppl.5501.Peer-Reviewed Original ResearchPET/CTProstate cancerPrimary endpointOccult diseaseSystemic therapyLocal therapyClinical managementNovel PET imaging agentBiochemically recurrent prostate cancerDrug-related SAEsEquivocal conventional imagingMetastatic prostate cancerRecurrent prostate cancerMajority of ptsBCR prostate cancerCurrent imaging modalitiesPET imaging agentCommon AEsDefinitive therapySecondary endpointsPSA responseMulticenter studyLower PSAPCa cellsF-DCFPyLLBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL
Gorin* M, Siegel B, Rowe S, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Morris M, Carroll P. LBA02-12 A MULTICENTER PHASE 3 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER: RESULTS FROM THE CONDOR TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000958.012.Peer-Reviewed Original ResearchF-DCFPyL PET/CTMulticenter phase 3 studyBiochemically recurrent prostate cancerPhase 3 studyRecurrent prostate cancerPET/CTProstate cancerCONDOR trial